GlaxoSmithKline Pharmaceuticals ... Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive ...

GlaxoSmithKline ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the countrys first single inhaler triple therapy (SITT ...

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...

all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter GSK announced that its monoclonal antibody, Nucala (mepolizumab ...

GSK said depemokimab would be exciting in terms of transition from Nucala. GSK says another product, gepotidacin, is the first in a new class of oral antibiotics for uUTI in over twenty years.

(Sharecast News) - GSK announced on Friday that its monoclonal antibody 'Nucala', or mepolizumab, has received approval from China's National Medical Products Administration for the treatment of ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

GSK's Nucala approved in China for CRSwNP, affecting 1/3 of 107 million sinusitis patients; third IL-5 condition indication in the region. Phase 3 trial shows Nucala reduces COPD exacerbations ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...